Sarita D Boyd

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection
    Sarita D Boyd
    Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA
    Clin Drug Investig . 2017
  2. pmc Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone
    Sarita D Boyd
    Office of Safety and Epidemiology, US Food and Drug Administration, Silver Spring, MD 20993, USA
    J Acquir Immune Defic Syndr 63:355-61. 2013
  3. pmc Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient
    Sarita D Boyd
    SAIC Frederick, Inc, MD, USA
    Antivir Ther 16:257-61. 2011
  4. pmc Management of HIV infection in treatment-naive patients: a review of the most current recommendations
    Sarita D Boyd
    Office of Safety and Epidemiology, Food and Drug Administration, Silver Spring, MD
    Am J Health Syst Pharm 68:991-1001. 2011

Detail Information

Publications4

  1. doi request reprint US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection
    Sarita D Boyd
    Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA
    Clin Drug Investig . 2017
    ..This article describes FDA's rationale for labeling determinations in situations where limited data made these decisions challenging...
  2. pmc Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone
    Sarita D Boyd
    Office of Safety and Epidemiology, US Food and Drug Administration, Silver Spring, MD 20993, USA
    J Acquir Immune Defic Syndr 63:355-61. 2013
    ....
  3. pmc Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient
    Sarita D Boyd
    SAIC Frederick, Inc, MD, USA
    Antivir Ther 16:257-61. 2011
    ..We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression...
  4. pmc Management of HIV infection in treatment-naive patients: a review of the most current recommendations
    Sarita D Boyd
    Office of Safety and Epidemiology, Food and Drug Administration, Silver Spring, MD
    Am J Health Syst Pharm 68:991-1001. 2011
    ..The most current guidelines issued by the Department of Health and Human Services (DHHS) on the management of human immunodeficiency virus (HIV) infection in treatment-naive patients are reviewed...